KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Notes Payables (2016 - 2025)

AbbVie (ABBV) has disclosed Notes Payables for 14 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • Quarterly Notes Payables changed N/A to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.5 billion for FY2025, N/A changed from the prior year.
  • Notes Payables for Q4 2025 was $2.5 billion at AbbVie, down from $3.8 billion in the prior quarter.
  • The five-year high for Notes Payables was $3.8 billion in Q3 2025, with the low at $1.0 million in Q4 2022.
  • Average Notes Payables over 5 years is $665.6 million, with a median of $14.0 million recorded in 2021.
  • The sharpest move saw Notes Payables crashed 92.86% in 2022, then soared 53000.0% in 2025.
  • Over 5 years, Notes Payables stood at $14.0 million in 2021, then plummeted by 92.86% to $1.0 million in 2022, then soared by 100.0% to $2.0 million in 2023, then surged by 50.0% to $3.0 million in 2024, then soared by 83200.0% to $2.5 billion in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $2.5 billion, $3.8 billion, and $2.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.